Amar Talwar who was seen in a short role in Karan Johar's Kabhi Khushi Kabhie Gham with Shah Rukh Khan, recently shared some unseen pictures of the superstar on Instagram. Fans have reacted to the ...

Speaking at the inaugural day of the WAVES Summit on Thursday, Shah Rukh Khan recently revealed that he enters a "meditative state" when not working. During a session titled The Journey ...

Swiss pharmaceutical giant Novartis is poised to expand its profile in the San Diego area, announcing plans to acquire Regulus Therapeutics, a local company on the cusp of bringing a potential ...

Shah Rukh Khan's not-so-small metallic hoops hung off his lobes discreetly, yet undeniably caught the eye (and light), giving him a regal and powerful feel as he walked towards the event's venue ...

Bollywood star Shah Rukh Khan may join the Marvel Cinematic Universe (MCU) as a superhero soon, as per fan theories that have gone viral on social media. MarvelLeaks22, a popular Marvel fan account on ...

Novartis (NYSE:NVS) has agreed to acquire biopharmaceutical firm Regulus Therapeutics (NASDAQ:RGLS) for an initial payment of $7.00 a share in cash at closing, or $0.8B. The upfront cash portion ...

Novartis NOVN0.71%increase; green up pointing triangle has agreed to acquire Regulus Therapeutics RGLS-0.38%decrease; red down pointing triangle for a total equity value of up to roughly $1.7 ...

Novartis AG agreed to buy US biotech Regulus Therapeutics Inc. in a deal that could be valued at up to $1.7 billion. The Swiss company will pay $7 a share in cash upfront through a subsidiary ...

(RTTNews) - Regulus Therapeutics (RGLS) has entered into an agreement and plan of merger with Novartis AG and an indirectly wholly owned subsidiary of Novartis, pursuant to which Novartis will ...

To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Novartis will pay $800 million upfront to acquire Regulus Therapeutics, a San Diego biotechnology company ...

Novartis' established global development and commercial capabilities will enable this important new medicine to reach patients if approved," said Jay Hagan, CEO of Regulus Therapeutics.

Novartis AG (NYSE:NVS) reported double-digit sales growth of 15% and core operating income growth of 27% for Q1 2025. The company achieved a core margin of 42.1%, reflecting a 400 basis points ...